The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma
Abstract
BACKGROUND: Doxorubicin exhibits high efficacy in malignant glioma cell cultures. Nonetheless, as a standard formulation, doxorubicin has not been used clinically, due to poor penetration of the blood‐brain barrier. Furthermore, doxorubicin is known to induce tumor resistance genes. To address both of these issues, the authors investigated the use of pegylated liposomal doxorubicin (Caelyx™; Essex Pharma, Munich, Germany) alone (Trial 1) and in combination with tamoxifen (Trial 2) in two sequentially performed nonrandomized prospective Phase II trials involving patients with recurrent high‐grade glioma. METHODS: Twenty patients were included in each trial. Progression‐free survival at 6 months (PFS‐6) and toxicity were the primary endpoints. Expression of the tumor resistance proteins multidrug resistance protein 1 (MDR‐1) and multiple resistance protein (MRP) was evaluated by immunohistochemical methods and by sestamibi–single‐photon emission computed tomography (SPECT). RESULTS: The overall response rate (including cases of disease stabilization) was 40% in both Trial 1 and Trial 2. PFS‐6 was 15%, and the median time to disease progression was 17 weeks. It is noteworthy that 40% of patients with Grade III tumors had long‐term responses, which lasted for up to 3 years. There was no significant difference between Trial 1 and Trial 2 in terms of efficacy. Both regimens were well tolerated, with the main side effect being palmoplantar erythrodysesthesia. The authors found no correlation between clinical response and expression of tumor resistance genes or between clinical response and SPECT data. CONCLUSIONS: Pegylated liposomal doxorubicin administered alone or in combination with tamoxifen is safe and moderately effective in patients with recurrent high‐grade glioma. None of the putative predictors for response that were evaluated proved to be significant in this setting. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 2×
“The median OS after treatment with PEG-DOX with or without TAM was 74 weeks, which is equal or superior to the survival durations associated with other second-line chemotherapy regimens.(2,31) As expected, patients with Grade III tumors had a significantly better median OS after diagnosis and exhibited a trend toward…”
ResultOutcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · cited 2×
“At the time of tumor recurrence, life expectancy is reduced to a few months.(2) To date, chemotherapy in this setting has not consistently demonstrated 1199”
BackgroundResult
Cited by
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792
The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
Deeken, J. F., & Löscher, W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2854 · Cited by 721
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Active targeting of brain tumors using nanocarriers
Béduneau, A., Saulnier, P., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.011 · Cited by 424
Colloidal carriers and blood–brain barrier (BBB) translocation: A way to deliver drugs to the brain?
Garcia-Garcia, E., Andrieux, K., Gil, S., & Couvreur, P. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.031 · Cited by 314
Norouzi, M., Yathindranath, V., Thliveris, J. A., Kopec, B. M., Siahaan, T. J., & Miller, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-68017-y · Cited by 292
Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Nanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
CNS Drug Delivery Systems: Novel Approaches
Pathan, S., Iqbal, Z., Zaidi, S., Talegaonkar, S., Vohra, D., Jain, G., Azeem, A., Jain, N., Lalani, J., Khar, R., et al. (2009) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221109787158355 · Cited by 193
“As several patents disclosed the use of liposomes as a potential delivery system for brain targeting, many research papers also supported the use of liposomes for CNS drug delivery as given in Table 3 below [105-111]:”
BackgroundFerraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Beier, C. P., Schmid, C., Gorlia, T., Kleinletzenberger, C., Beier, D., Grauer, O., Steinbrecher, A., Hirschmann, B., Brawanski, A., Dietmaier, C., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-308 · Cited by 125
Self-citationAnanda, S., Nowak, A. K., Cher, L., Dowling, A., Brown, C., Simes, J., & Rosenthal, M. A. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.02.026 · Cited by 116
Pegylated Liposomal Doxorubicin in Recurrent Malignant Glioma: Analysis of a Case Series
Glas, M., Koch, H., Hirschmann, B., Jauch, T., Steinbrecher, A., Herrlinger, U., Bogdahn, U., & Hau, P. (2007) · Oncology · doi:10.1159/000113052 · Cited by 30
Self-citation
Metadata
- Authors
- Hau, P., Fabel, K., Baumgart, U., Rümmele, P., Grauer, O., Bock, A., Dietmaier, C., Dietmaier, W., Dietrich, J., Dudel, C., Hübner, F., Jauch, T., Drechsel, E., Kleiter, I., Wismeth, C., Zellner, A., Brawanski, A., Steinbrecher, A., Marienhagen, J., & Bogdahn, U.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-02-06
- Volume
- 100
- Issue
- 6
- Pages
- 1199-1207
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2081215365
- Cited by
- 196
- References
- 3
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.